Lee’s Pharma to develop Windtree drug in China; Acurx shares PhIIb antibiotic data; Granata raises $14M

Plus, news about Prota Therapeutics and Vaxart:

Windtree Therapeutics inks deal with Hong Kong group: Per the terms, Lee’s Pharmaceutical will pay Windtree up to $138.1 million to develop and commercialize its acute heart failure and cardiogenic shock treatment in Greater China. The drug istaroxime activates…
Click here to view original post